Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Dec 9 2010

Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has amended its June 15, 2010 agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com) to immediately include Mexico in the Territory under the Sales, Marketing, Distribution and Supply Agreement. Under this Agreement, GP Pharm Mexico will be responsible for gaining regulatory approval in Mexico for Ampligen®, an experimental therapeutic, to treat Chronic Fatigue Syndrome ("CFS") in Mexico and for commercializing Ampligen® for this indication in Mexico. The Company has granted GP Pharm the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones.

Thomas Kenwood Equels, Executive Vice Chairman of Hemispherx and the leader of its world-wide marketing efforts, stated, "We are very pleased by the diligent efforts of GP Pharm in Argentina and encouraged that GP Pharm Mexico is prepared to undertake efforts immediately to gain approval and commercialize Ampligen for CFS in Mexico.  I continue to believe this relationship will eventually lead to opening large markets for Hemispherx's platform technologies in Latin America."

Mr. Braver of GP Pharm said, "Our management at GP Pharm Mexico, an operation we established earlier this year, have learned that there are over 500,000 cases of Chronic Fatigue Syndrome in Mexico and, as with other CFS sufferers around the globe, these people have no effective treatment for this debilitating disease. We are pleased by the expansion of our relationship with Hemispherx and are committed to the broad commercialization of Ampligen® in Latin America."

SOURCE Hemispherx Biopharma, Inc.